Category: 53788-12-8

On August 31, 1977, Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta; Momonoi, Kaishu; Yasuda, Takashi; Kasuya, Kyoko published an article.Name: 4-Ethyl-piperazine-1-carbonyl chloride The title of the article was Studies on β-lactam antibiotics for medicinal purposes. I. Synthesis of D(-)-α-[(monooxo)-1-piperazinecarboxamido]benzylpenicillins and structure-antibacterial activity. And the article contained the following:

D-(-)-I (R1 = Me, Et, PhCH2, Ac, MeSO2, Ph), D-(-)-II (R1 = C1-4 alkyl, PhCH2, Ac, EtCO, PrCO, BuCO, ClCH2CO, MeSO2), and D-(-)-III (R1 = H, C1-4 alkyl, PhCH2, allyl) were prepared by N-acylation of aminobenzylpenicillin (IV). In vitro bactericidal activity of I – III against S. aureus, E. coli, P. aeruginosa, P. vulgaris, and K. pneumoniae decreased in the order of II > I > III. The bactericidal activity of these compounds against P. aeruginosa and K. pneumoniae was stronger than that of IV or carbenicillin. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Name: 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to bactericides piperazinecarboxamidobenzylpenicillin, piperazinecarboxamidobenzylpenicillin, penicillin piperazinecarboxamidobenzyl, benzylpenicillin piperazinecarboxamido, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines and other aspects.Name: 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2006, Kauffman, Goss Stryker; Li, Chao; Lippa, Blaise Scott; Morris, Joel; Pan, Gonghua published a patent.Safety of 4-Ethyl-piperazine-1-carbonyl chloride The title of the patent was Preparation of bicyclic heteroaromatic derivatives as anticancer agents. And the patent contained the following:

The title compounds I [X, Z, V and W = N or CR1 (R1 = H, halo, CN, etc.); R4 = H, alkyl, (CR11R12)t(aryl), (CR11R12)t(4-10 membered heterocyclyl); R5 = H, alkyl, or R4 and R5 are taken together to form an oxo moiety; R6 and R7 are taken together to form a 4-10 membered (bi)cyclic or hetero(bi)cyclic ring system; B represents a fused 5-6 membered aromatic ring containing 0-2 heteroatoms; with provisos], useful for treating abnormal cell growth in mammals (no specific data given), were prepared Thus, reacting 4-chloro-7H-pyrrolo[2,3-d]pyrimidine with tert-Bu 5-chloro-1,2-dihydro-1’H-spiro[indole-3,4′-piperidine]-1′-carboxylate followed by deprotection afforded II. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds I and to pharmaceutical compositions for treating such disorders which contain the compounds I. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Safety of 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to bicyclic heteroaromatic pyrrolopyrimidine pyrazolopyrimidine spiroindolepiperidine preparation antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 28, 2013, Kolbe, Ludger; Scherner, Cathrin published a patent.Related Products of 53788-12-8 The title of the patent was Heterocyclocarbonyl aminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonyl aminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin. And the patent contained the following:

The invention relates to cosmetic and dermatol. preparations having an effective content of one or more heterocyclocarbonyl aminothiazoles of formula I and to the use thereof for the cosmetic or dermatol. treatment and/or prophylaxis of undesired skin pigmentation. Compounds of formula I wherein R1 is morpholino, piperidin-1-yl, piperazin-1-yl, etc.; R2 is H, (un)branched C1-24 alkyl, (un)branched C1-24 alkenyl, etc.; X is H, Ph, 2,4-dihydroxyphenyl, etc.; Y is H, aryl, COO-aryl, etc.; as free bases and their cosmetic and dermatol. acceptable salts, are claimed. Example compound II was prepared by thioamidation of 4-morpholinecarbonyl chloride with thiourea followed by cyclocondensation of the resulting N-morpholinocarbonylthiourea with 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone. All the invention compounds were evaluated for their ability to inhibit pigmentation. From the assay, it was determined that example compound II exhibited 97% of inhibition. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Related Products of 53788-12-8

The Article related to heterocyclocarbonyl aminothiazole preparation cosmetic dermatol treatment pigmentation, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Related Products of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 28, 2013, Kolbe, Ludger; Scherner, Cathrin published a patent.Computed Properties of 53788-12-8 The title of the patent was Heterocyclocarbonyl aminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonyl aminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin. And the patent contained the following:

The invention relates to cosmetic and dermatol. preparations having an effective content of one or more heterocyclocarbonyl aminothiazoles of formula I and to the use thereof for the cosmetic or dermatol. treatment and/or prophylaxis of undesired skin pigmentation. Compounds of formula I wherein R1 is morpholino, piperidin-1-yl, piperazin-1-yl, etc.; R2 is H, (un)branched C1-24 alkyl, (un)branched C1-24 alkenyl, etc.; X is H, Ph, 2,4-dihydroxyphenyl, etc.; Y is H, aryl, COO-aryl, etc.; as free bases and their cosmetic and dermatol. acceptable salts, are claimed. Example compound II was prepared by thioamidation of 4-morpholinecarbonyl chloride with thiourea followed by cyclocondensation of the resulting N-(morpholinocarbonyl)thiourea with 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone. All the invention compounds were evaluated for their ability to inhibit pigmentation. From the assay, it was determined that example compound II exhibited 97% of inhibition. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Computed Properties of 53788-12-8

The Article related to heterocyclocarbonyl aminothiazole preparation cosmetic dermatol treatment pigmentation, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Computed Properties of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 1977, Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta; Momonoi, Kaishu; Yasuda, Takashi; Kasuya, Kyoko published an article.Name: 4-Ethyl-piperazine-1-carbonyl chloride The title of the article was Studies on β-lactam antibiotics for medicinal purposes. I. Synthesis of D(-)-α-[(monooxo)-1-piperazinecarboxamido]benzylpenicillins and structure-antibacterial activity. And the article contained the following:

D-(-)-I (R1 = Me, Et, PhCH2, Ac, MeSO2, Ph), D-(-)-II (R1 = C1-4 alkyl, PhCH2, Ac, EtCO, PrCO, BuCO, ClCH2CO, MeSO2), and D-(-)-III (R1 = H, C1-4 alkyl, PhCH2, allyl) were prepared by N-acylation of aminobenzylpenicillin (IV). In vitro bactericidal activity of I – III against S. aureus, E. coli, P. aeruginosa, P. vulgaris, and K. pneumoniae decreased in the order of II > I > III. The bactericidal activity of these compounds against P. aeruginosa and K. pneumoniae was stronger than that of IV or carbenicillin. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Name: 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to bactericides piperazinecarboxamidobenzylpenicillin, piperazinecarboxamidobenzylpenicillin, penicillin piperazinecarboxamidobenzyl, benzylpenicillin piperazinecarboxamido, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines and other aspects.Name: 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2006, Kauffman, Goss Stryker; Li, Chao; Lippa, Blaise Scott; Morris, Joel; Pan, Gonghua published a patent.Safety of 4-Ethyl-piperazine-1-carbonyl chloride The title of the patent was Preparation of bicyclic heteroaromatic derivatives as anticancer agents. And the patent contained the following:

The title compounds I [X, Z, V and W = N or CR1 (R1 = H, halo, CN, etc.); R4 = H, alkyl, (CR11R12)t(aryl), (CR11R12)t(4-10 membered heterocyclyl); R5 = H, alkyl, or R4 and R5 are taken together to form an oxo moiety; R6 and R7 are taken together to form a 4-10 membered (bi)cyclic or hetero(bi)cyclic ring system; B represents a fused 5-6 membered aromatic ring containing 0-2 heteroatoms; with provisos], useful for treating abnormal cell growth in mammals (no specific data given), were prepared Thus, reacting 4-chloro-7H-pyrrolo[2,3-d]pyrimidine with tert-Bu 5-chloro-1,2-dihydro-1’H-spiro[indole-3,4′-piperidine]-1′-carboxylate followed by deprotection afforded II. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds I and to pharmaceutical compositions for treating such disorders which contain the compounds I. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Safety of 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to bicyclic heteroaromatic pyrrolopyrimidine pyrazolopyrimidine spiroindolepiperidine preparation antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Dong, Ze-Xi; Shi, Zhi-Hao; Li, Nian-Guang; Zhang, Wei; Gu, Ting; Zhang, Peng-Xuan; Wu, Wen-Yu; Tang, Yu-Ping; Fang, Fang; Xue, Xin; Li, He-Min; Cheng, Hai-Bo; Yang, Jian-Ping; Duan, Jin-Ao published an article in 2016, the title of the article was Design, Synthesis, and Biological Evaluation of Scutellarein Derivatives Based on Scutellarin Metabolic Mechanism In Vivo.Synthetic Route of 53788-12-8 And the article contains the following content:

Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. Their thrombin inhibition activities were tested through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB). The antioxidant activities of these target products were assessed by 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) assay and the ability to protect PC12 cells against H2O2-induced cytotoxicity, and their solubilities were evaluated by UV spectrophotometer. The results showed that the two iso-Pr groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Synthetic Route of 53788-12-8

The Article related to scutellarein derivative neuroprotectant antioxidant, antioxidant, scutellarein, scutellarin, solubility, thrombin, Pharmacology: Effects Of Nervous System- and Behavior-Affecting Drugs and Neuromuscular Agents and other aspects.Synthetic Route of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 22, 1998, Shimizu, Hideaki; Abe, Atsuhiro; Yaegashi, Takashi; Sawada, Seigo; Nagata, Hiroshi published a patent.HPLC of Formula: 53788-12-8 The title of the patent was Preparation of taxane derivatives as antitumors and pharmaceuticals containing them. And the patent contained the following:

The title compounds [I; X, Y = CO-A-B; A = bond, -R-CO-, -R-OCO-, -R-NHCO-; R = alkylene, phenylene; B = (un)substituted heterocyclyl, e.g., piperazin-1-yl; Z = H, trialkylsilyl, trihaloalkoxycarbonyl; Bz = benzoyl], II [R7 = H, alkoxycarbonyl, aralkyloxycarbonyl; R8, R9 = H, alkyl, haloalkyl, etc.] or their salts are prepared Thus, 7-O-triethylsilyl-10-deacetylbaccatin III was reacted with 4-(dimethylamino)piperidinocarbonyl chloride (also prepared) in THF-hexane containing BuLi at -40° to room temperature to give 90% 10-O-(4-dimethylaminopiperidinocarbonyl)-7-O-triethylsilyl-10-deacetylbaccatin III. This was reacted with (4S,5R)-3-(benzyloxycarbonyl)-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylic acid to give the title compound III. These compounds exhibit a high solubility in water and showed excellent antitumor activity. In an ELISA screening using human oral cancer KB cells, the GI50 for 13-O-[3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionyl]-10-O-(4-dipropylaminopiperidinocarbonyl)-10-deacetylbaccatin III (also prepared) was 0.78 ng/mL vs. 2.0 ng/mL for taxol. The solubility of 13-O-[3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionyl]-10-O-(4-dimethylaminopiperidinocarbonyl)-10-O-deacetylbaccatin III (also prepared) in water was 1260 μg/mL vs. 0.4 μg/mL for taxol. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).HPLC of Formula: 53788-12-8

The Article related to taxane derivative preparation antitumor solubility, Terpenes and Terpenoids: Diterpenes (C20), Including Gibberellins, Retinoids, Quassinoids, and Tocopherols and other aspects.HPLC of Formula: 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 1, 2012, Li, Qingeng; Wang, Tao; Xia, Biao; Guo, Bin published a patent.Category: piperazines The title of the patent was Novel 7,10-O,O-dimethyldocetaxel derivative, its preparation process and application for treating cancers. And the patent contained the following:

The invention disclosed a kind of 7,10-O,O-dimethyldocetaxel derivatives and their salts, preparation method and medical application as antitumor agents. The claimed title compounds are shown in structure I (R = H, Me, Et, Pr, iso-Pr, Bu, iso-Bu, or CH2-Ph; HB = inorganic or organic acid from HCl, HBr, HNO3, acetic acid, lactic acid, or tartaric acid etc.). The claimed compounds are prepared with II via esterification etc. multiple steps (procedure given). The obtained compounds and pharmaceutically acceptable salts can be used for preparing water-soluble medicals for treating cancers such as breast cancer, lung cancer and ovarian cancer without side effect, high safety and controlled quality (no data provided). The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Category: piperazines

The Article related to dimethyldocetaxel derivative salt synthesis esterification antitumor agent, Terpenes and Terpenoids: Diterpenes (C20), Including Gibberellins, Retinoids, Quassinoids, and Tocopherols and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 24, 2016, Li, Qingshan; Zhang, Yuanlin; Feng, Xiue published a patent.Formula: C7H13ClN2O The title of the patent was Preparation of N-formyloxy substituted chlorobenzophenone derivatives. And the patent contained the following:

The invention discloses structure construction of N-formyloxy substituted chlorobenzophenone novel derivative I; in its structure R is N-formyl group; wherein two hydrogen atoms on nitrogen atom are substituted by two same straight-chain alkyls or branched alkyls with carbon atom of 1-4, or two hydrogen atoms on nitrogen atom are substituted to generate pyrrole ring, piperazine ring, piperidine ring, morpholine ring. Meanwhile, the invention discloses application of the N-formyloxy substituted chlorobenzophenone novel derivative and its pharmaceutical salts in preparing medicines for cardiovascular disease caused by vascular endothelial cell injury. The N-formyloxy substituted chlorobenzophenone derivative of the invention can remarkably improve protection activity to H2O2 induced vascular endothelial cell injury, and it has important application prospect in preparing related medicine for preventing or treating cardiovascular disease caused by vascular endothelial cell injury. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Formula: C7H13ClN2O

The Article related to preparation formyloxy substituted chlorobenzophenone derivative, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Ketones and Derivatives, Including Quinones and Sulfur Analogs and other aspects.Formula: C7H13ClN2O

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics